Beam Therapeutics (BEAM)
In a report released today, Rick Bienkowski from Leerink Partners maintained a Buy rating on Beam Therapeutics, with a price target of $121.00. The company’s shares closed last Monday at $69.49, close to its 52-week low of $56.34.
According to TipRanks.com, Bienkowski is ranked #7089 out of 7758 analysts.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Beam Therapeutics with a $122.00 average price target, representing a 73.0% upside. In a report issued on January 5, Guggenheim also initiated coverage with a Buy rating on the stock with a $130.00 price target.
Karyopharm Therapeutics (KPTI)
In a report released today, Jonathan Chang from Leerink Partners maintained a Hold rating on Karyopharm Therapeutics, with a price target of $8.00. The company’s shares closed last Monday at $7.47.
According to TipRanks.com, Chang has currently 0 stars on a ranking scale of 0-5 stars, with an average return of
Currently, the analyst consensus on Karyopharm Therapeutics is a Moderate Buy with an average price target of $12.71, which is an 81.6% upside from current levels. In a report issued on January 6, RBC Capital also maintained a Hold rating on the stock with a $9.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on BEAM:
- Alibaba: Better Days Ahead… but Still a While Away, Says JPMorgan
- Mizuho Securities Keeps Their Buy Rating on Arcus Biosciences (RCUS)
- Greenbrier Shares Drop 5.8% Despite Strong Q1 Result
- Needham Maintains a Hold Rating on Irhythm Technologies (IRTC)
- Top Metaverse Stocks to Watch: Nvidia & Matterport